RT Journal Article
SR Electronic
T1 Factors shaping vaginal microbiota long-term community dynamics in young adult women
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.08.24305448
DO 10.1101/2024.04.08.24305448
A1 Kamiya, Tsukushi
A1 Tessandier, Nicolas
A1 Elie, Baptiste
A1 Bernat, Claire
A1 Boué, Vanina
A1 Grasset, Sophie
A1 Groc, Soraya
A1 Rahmoun, Massilva
A1 Selinger, Christian
A1 Humphrys, Michael S.
A1 Bonneau, Marine
A1 Graf, Christelle
A1 Foulongne, Vincent
A1 Reynes, Jacques
A1 Tribout, Vincent
A1 Segondy, Michel
A1 Boulle, Nathalie
A1 Ravel, Jacques
A1 Murall, Carmen Lía
A1 Alizon, Samuel
YR 2025
UL http://medrxiv.org/content/early/2025/01/27/2024.04.08.24305448.abstract
AB The vaginal microbiota is known to affect women’s health. Yet, there is a notable paucity of high-resolution follow-up studies lasting several months, which would be required to interrogate the long-term dynamics and associations with demographic and behavioural covariates. Here, we present a high-resolution longitudinal cohort of 125 women followed for a median duration of 8.6 months, providing 11 samples per woman. Using a hierarchical Bayesian Markov model, we characterised the patterns of vaginal microbiota community persistence and transition, simultaneously estimated the impact of 16 covariates and quantified individual variability among women. We showed that ‘optimal’ (Community State Type (CST) I, II, and V) and ‘sub-optimal’ (CST III) communities are more stable over time than ‘non-optimal’ (CST IV) ones. Furthermore, we found that some covariates — most notably alcohol consumption — impacted the probability of shifting from one CST to another. We performed counterfactual simulations to confirm that alterations of key covariates, such as alcohol consumption, could shape the prevalence of different microbiota communities in the population. Finally, our analyses indicated that there is a relatively canalised pathway leading to the deterioration of vaginal microbiota communities, whereas the paths to recovery can be highly individualised among women. In addition to providing one of the first insights into vaginal microbiota dynamics over a year, our study showcases a novel application of a hierarchical Bayesian Markov model to clinical cohort data with many covariates. Our findings pave the way for an improved mechanistic understanding of microbial dynamics in the vaginal environment and the development of novel preventative and therapeutic strategies to improve vaginal health.Competing Interest StatementJReynes reports personal fees from Gilead (payment or honoraria for lectures, presentations, or educational events) Merck (payment or honoraria for lectures, presentations, or educational events), Moderna (honoraria for lectures, or manuscript writing), Shionogi (honoraria for presentation) and ViiV Healthcare (consulting and payment or honoraria for lectures, presentations, or educational events) and support for attending meetings and/or travel from Gilead and Pfizer, all outside of the submitted work. JRavel is co-founder of LUCA Biologics, a biotechnology company focusing on translating microbiome research into live biotherapeutics drugs for women's health. He is Editor-in-Chief at Microbiome. All the other authors do not report any conflict of interest.Clinical Protocols http://dx.doi.org/10.1136/bmjopen-2018-025129 Funding StatementThis project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No 648963, to SA). The authors acknowledge further support from the Fondation pour la Recherche Medicale (to TK), the Agence Nationale de la Recherche contre le SIDA (ANRS-MIE, to NT and OS), and the MemoLife Labex (to BE).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The PAPCLEAR study was promoted by the CHU of Montpellier (France). This study has been approved by the Comité de Protection des Personnes (CPP) Sud Mediterranée I (reference number 2016-A00712-49); by the Comité Consultatif sur le Traitement de l'Information en matigre de Recherche dans le domaine de la Santé (reference number 16.504); by the Commission Nationale Informatique et Libertés (reference number MMS/ ABD/ AR1612278, decision number DR-2016-488), by the Agence Nationale de Securité du Medicament et des Produits de Sante (reference 20160072000007), and is registered at ClinicalTrials.gov under the ID NCT02946346.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll the data analysed in the present work along with the scripts are available at https://doi.org/10.57745/FHQR9Zhttps://doi.org/10.57745/FHQR9Z